Biodesix, Inc. (BDSX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 58/100 (HIGH), 8.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.29% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
- Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
- Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
- Biodesix to Participate in Upcoming Investor Conferences
- What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
- Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
- Biodesix (BDSX) Q2 2026 Earnings Call Transcript
- Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Biodesix, Inc..
Full BDSX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.